Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival
Open Access
- 22 August 2013
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 122 (8) , 1384-1394
Abstract
Better treatment is required for older patients with acute myeloid leukemia (AML) not considered fit for intensive chemotherapy. We report a randomized comparison of low-dose Ara-C (LDAC) vs the novel nucleoside, clofarabine, in untreated older patients with AML and high-risk myelodysplastic syndrome (MDS). A total of 406 patients with de novo (62%), secondary disease (24%), or high-risk MDS (>10% marrow blasts) (15%), median age 74 years, were randomized to LDAC 20 mg twice daily for 10 days every 6 weeks or clofarabine 20 mg/m2 on days 1 to 5, both for up to 4 courses. These patients had more adverse demographics than contemporaneous intensively treated patients. The overall remission rate was 28%, and 2-year survival was 13%. Clofarabine significantly improved complete remission (22% vs 12%; hazard ratio [HR] = 0.47 [0.28-0.79]; P = .005) and overall response (38% vs 19%; HR = 0.41 [0.26-0.62]; P < .0001), but there was no difference in overall survival, explained by poorer survival in the clofarabine patients who did not gain complete remission and also following relapse. Clofarabine was more myelosuppressive and required more supportive care. Although clofarabine doubled remission rates, overall survival was not improved overall or in any subgroup. The treatment of patients of the type treated here remains a major unmet need. This trial was registered at www.clinicaltrials.gov as #ISRCTN 11036523. Key Points In older patients with AML who are not suitable for intensive treatment, clofarabine doubles remission rates Survival is not improved compared with low-dose Ara-CKeywords
This publication has 19 references indexed in Scilit:
- Phase II Study of Clofarabine Monotherapy in Previously Untreated Older Adults With Acute Myeloid Leukemia and Unfavorable Prognostic FactorsJournal of Clinical Oncology, 2010
- Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia RegistryBlood, 2009
- Hematopoietic cell transplantation–specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiencesBlood, 2007
- A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatmentCancer, 2007
- Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survivalLeukemia, 2005
- Cytotoxicity and pharmacokinetics of cladribine metabolite, 2-chloroadenine in patients with leukemiaCancer Letters, 2004
- Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid LeukemiaJournal of Clinical Oncology, 2003
- Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemiaBlood, 2003
- Synthesis and biological activity of 2'-fluoro-2-halo derivatives of 9-.beta.-D-arabinofuranosyladenineJournal of Medicinal Chemistry, 1992
- 2-Fluoro-ATP: A toxic metabolite of 9-β-D-arabinosyl-2-fluoroadenineBiochemical and Biophysical Research Communications, 1983